Zacks reports that according to Wall Street analysts, ImmunoGen, Inc. (NASDAQ:IMGN) is to declare ($0.19) Earnings Per Share (EPS) for the current quarter. Estmates have been given by five analysts. ($0.14) is the highest estimated EPS and ($0.23) is the lowest. Same quarter, last year the company reported an EPS of ($0.15). This is an indicator of a 26.7% negative year-over-year growth. On Friday, 6th November, the firm will announce its earnings report.
ImmunoGen, Inc. (NASDAQ:IMGN) EPS- Detailed Report
The average full-year earnings of ImmunoGen, Inc. (NASDAQ:IMGN) for the current year is estimated to be ($0.70) per share, suggests analysts. The estimated EPS range is to vary from ($0.79) to ($0.62). Analysts’ estimates for the next fiscal year estimates the company to reflect earnings per share of ($0.76) and an EPS range varying between ($0.90) to ($0.66).
On Friday, 31st July, the quarterly earnings were released by ImmunoGen (NASDAQ:IMGN). For the quarter, the company reported earnings per share of ($0.14), matching the upper limit of the estimated consensus of ($0.18) by $0.04 presented by Thomson Reuters. During the quarter, the biotechnology company reported $12.03 million as revenue. Analysts estimated the revenue to be $14.29 million.
Various research analysts put forth their opinion about ImmunoGen (NASDAQ:IMGN).On Friday, 18th September, a research note suggested that William Blair reissued a ‘buy’ rating on the company. On Friday, 2nd October Guggenheim boosted the company’s rating from ‘neutral’ to ‘buy.’ It set a price target of $14.00 for ImmunoGen.
According to a research note, a ‘buy’ rating was reaffirmed by Canaccord Genuity on Monday, 3rd August. SVB Leerink increased the price target from $4.00 to $5.00. It also issued a ‘market perform’ rating for ImmunoGen (NASDAQ:IMGN). A research note issued on Tuesday, 29th September reported that JPMorgan Chase & Co assumed coverage on the biotechnology firm. A ‘neutral’ rating was also issued.
ImmunoGen’s stock has been given a ‘hold’ rating by 4 equities research analysts. It has also received a ‘buy’ rating from six analysts. The present consensus rating of ImmunoGen (NASDAQ:IMGN) is ‘buy’ and $8.75 is the consensus target price.
ImmunoGen (NASDAQ:IMGN) – Other Facts
ImmunoGen traded up on Friday from $0.52 to $4.82. The trading volume of ImmunoGen (NASDAQ:IMGN) was 16,070,075 shares, compared to 2,806,103; its average volume. The market cap of the firm is $841.29 million, -11.21 is the PE ratio and 2.06 is the beta. The 12-month low of the company $1.95 and $7.07 is the 12-month high.
